Introduction
Prolactin (PRL) is an anterior pituitary hormone, which together with the growth hormone (GH) and placental lactogens (PLs) form a family of hormones that probably result from the duplication of an ancestral gene (Cooke et al., 1981; Miller and Eberhardt, 1983; Walker et al., 1991) . PLs, which are found only in mammals have presumably an alternative genetic origin, either GH lineage in primate or the PRL lineage in nonprimate animals (Miller and Eberhardt, 1983; Walker et al., 1991) .
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cally distant vertebrate species show a high degree of divergence (Yasuda et al., 1987) . Studies on the secondary structure of PRL have shown, that PRL is an all-a-heliks protein and contains about 50% of a-helices (Bewley and Li, 1972; Bole-Feysot et al., 1998) , while the remainder of the proteins appear to fold into nonorganized loop structures. Human PRL tertiary structure is predicted to fold in a four-helix bundle (Bole-Feysot et al., 1998) .
Many variants of PRL, which have been identified in mammals, can be formed theoretically by post-transcriptional processing of primary transcript and/or post-translational modification of protein (Ben-Jonathan et al., 1996) . It is well recognized that circulating PRL may exist in little form (monomeric), big form and big-big form (macroprolactin), with molecular masses of 23, 50 and 150-170 kDa, respectively (Diver et al., 2001; Fahie-Wilson et al., 2005; Galoiu et al., 2005; Ellis et al., 2007) . Generally, only some big forms retain PRL-like activity, but others have unique properties or no known functions (Sinha, 1995) . Monomeric form of PRL which normally is up 85-90% of serum prolactin, big PRL form <10%, and big-big prolactin <3% (Galoiu et al., 2005) . However, in some humans, the big-big form variant represents the majority of circulating PRL (Jackson et al., 1985) .
Big prolactin is a complex of little PRL and another serum components, possible prolactin-binding protein or represents a dimmer of little prolactin (Kline and Clevenger 2001; Piketly et al., 2002) . The big-big prolactin was identified mainly as a high stability complex of peripheral origin from monomeric prolactin of any source (pituitary or extrapituitary) and immunoglobulin G (Hattori et al., 1992; Bonhoff et al., 1995; Cavaco et al., 1995) . Because of its low clearance macroprolactinaemia determines high level of PRL with normal pituitary function (Galoiu et al., 2005) . Most frequent causes of high levels of PRL are pituitary tumors, drugs and hypothyroidism. It is more frequent in patients with autoimmune diseases, such as synthesis lupus erythematosus (Ahlquist et al., 1998; Leanos et al., 1998; Pacilio et al., 2001) . Macroprolactin appears to have negligible bioactivity at human prolactin receptor in vivo, but in vitro it seems that it has normal biological activity (Leite et al., 1992; Galoiu et al., 2005) .
There are also smaller molecular mass variants of PRL, which are produced by proteolytic cleavage, both at the sites of synthesis or at some target tissues (Casabiell et al., 1989; Powers and Hatala, 1990; Baldocchi et al., 1992; DeVito et al., 1992; Ben-Jonathan et al., 1996) . For example, the 22-kDa form PRL-1-173 is generated by kallikrein a trypsyn-like serine protease that is aboundant in lactotrophs (Powers and Hatala, 1990) . The production of this form is sex-dependent and is stimulated by oestrogen and suppressed by dopamine (Anthony et al., 1993) . It is likely, that PRL-1-173 plays a potential role in female reproduction.
The 16-kDA PRL binds weakly to PRL receptors and its antiangiogenic activity, shown in vivo and in vitro, is mediated by high affinity receptor distinct from PRL receptors (Clapp and Weiner, 1992) . The 16-kDa PRL formation proceeds in two steps: cleavage by a cathepsin D-like protease, which generates a two-chain molecule joined by a disulphide bond followed by a reduction yielding 16-kDa and 8-kDa fragments. The 16-kDa has been detected in the hypothalamus, pituitary and serum, accounting for about 1% of the total secreted PRL (Ben-Jonathan et al., 1996) . The variants of PRL with molecular sizes 8, 16, 24-kDa were found in the hypothalamus of rats, and variants ranging from 11 to 46 were identified in the human lymphocytes (Ben-Jonathan et al., 1996) .
Prolactin variants, ranging from 14 to <90 kDa, released in vitro from the pituitary of lactating, pregnant and steroid-treated female or male rats stimulates PRL secretion from pituitary lactotrophs of male rats (Mena et al., 2010) . The main effects on PRL release are provoked by the 23 to 46 kDa PRL variants (Mena et al., 2010) . Glycosylated PRL is detected in pituitary and plasma, composing 1%, 15% and 50% of total PRL in bovine, human and porcine pituitaries, respectively (Sinha, 1995) .
There is evidence for constitutive, rather than regulated, secretion of glycosylated PRL (Ben-Jonathan et al., 1996) . It varies among species and their heterogeneity accounts for differences in bioactivity, immunoreactivity, receptor bindings and often decreases PRL bioactivity (Ben-Jonathan et al., 1996; Mena et al., 2010) .
Pituitary and extrapituitary producing cells
The lactotroph cells of the pituitary gland are non-homologous group of cells; these cells can be separate into subsequent subpopulation based on morphological criteria: density granulated cells that function as storage or resting cells and sparsely granulated secretory cells that are particularly abundant in prolactinomas (Ben-Jonathan et al., 1996) . Functionally, lactotrophs are also heterogeneous with respect to basal hormone release, electrical activity and responsiveness to releasing inhibitory factors, including regional differences in exposure to hypothalamic or posterior pituitary factors (Ben-Jonathan et al., 1996; Mena et al., 2010) .
In rodents, the three morphological types of lactotrophs have been defined by electron microscopy (Christian et al., 2007) . Type I 'classical lactotrophs' contain large irregular shaped electro-dense secretory granules (diameter 300-700 nm), type II cells contain numerous sized spherical electron dense granules (diameter 200-250 nm), and type III cells, which have small (100-200 nm) spherical granules. In male and female young rats of 10 days of age the majority of lactotrophs in pituitary are type III, by 30 days of age, the lactotrophs population comprises mostly type II cells, at 60 days of age, the proportion of PRL cell types in male pituitary changes significantly (approximately 40% type I, 50% type II, 10% type III cells) compared to females (80-90% type I, 10-20% type II, 2-4% type III). Although differentiation of these types of lactotrophs is not known, it is suggested that they might represent different stages of cell maturation. So, the function of lactotrophs is derived from structural polymorphism, local synthesis, divergent intracellular signaling pathways and target tissue (Ben-Jonathan et al., 1996; Stojilkovic et al., 2010) . Indeed clonal cell line GH 3 produced prolactin and growth hormone and express thyrotropin releasing hormone (TRH), vasoactive intestinal polypeptide (VIP) and epidermal growth factor receptors, but not dopamine (DA) receptors (Ben-Jonathan et al., 1996; Stojilkovic et al., 2010) . The 235-1 lactotroph cell line express the PRL gene. They secrete PRL in CA ++ -dependent manner. Similarly, the MMQ cells (a unique prolactin-secreting rat pituitary cell line) secrete prolactin only in a CA ++ -dependent manner and express functionally DA-D 2 receptor, endothelin receptor (ETa) and oxytocin receptor (Stojilkovic et al., 2010) . The PRL that is produced by different cell types can act in direct fashion as a growth factor, neurotransmitter or immunomodulator in auto or paracrine manner (Bole-Feysot et al., 1998) .
The PRL is involved in many (more than 300) biological function, including water and electrolyte balance, growth and development, endocrinology and metabolism, brain function and behaviour, reproduction, immunoregulation and protection and also its action associated with pathological disease state (Bole-Feysot et al., 1998) .
Besides of the pituitary lactotrophs, PRL gene expression has been detected in many extrapituitary PRL producing cells: in various region in the brain, decidua, myometrium lacrimal gland, thymus, spleen, circulating lymphocytes and lymphoid cells from marrow, mammary epithelial cells and tumor, skin fibroblasts and sweet glands (Ben-Jonathan et al., 1996; Bole-Feysot et al., 1998).
The hypophysectomized rats, just after hypophysectomy, retain about 20% of biologically active form of PRL in blood, which increases to approximately to 50% in normal level with time (Nagy and Berczi, 1991; Bole-Feysot et al., 1998) . Neutralization of circulating PRL with PRL-antibodies results in immune disfunction and death of animals indicating that extrapituitary PRL can compensate for pituitary PRL (Nagy and Berczi, 1991) .
Factors inhibiting prolactin secretion
Different morphological subtypes of lactotrophs display differential secretory activity in response to various stimulatory and inhibitory factors.
Consistent with a high basal level of PRL secretion from a pituitary gland, the predominant hypothalamic influence on PRL release is inhibitory rather than stimulatory and is mainly exerted by a neurotransmitter DA, acting through the DA-D 2 membrane receptors, which are coupled with Gi/o signaling pathway (Ben-Jonathan and Hnasko, 2001). DA inhibits PRL release decreasing the cytosolic free calcium concentration (Lambert and Macleod, 1990) and suppresses PRL mRNA level (Ben-Jonathan and Hnasko, 2001) . This inhibitory effect of DA on PRL secretion is exerted principally by reducing intracellular phospholipase signaling pathway and/or pituitary-specific transcription factor Pit-1 ( Caccavelli et al., 1992; Lew and Elsholtz, 1995; Ben-Jonathan and Hnasko, 2001) . In rats, DA reaches the lactotrophs in the anterior lobe of the pituitary gland from each 3 hypothalamic dopaminergic systems: the tuberoinfundibular (TIDA), tuberohypophyseal (THDA) and periventricular hypophyseal (PHDA) DA cells (De Maria et al., 1998; Freeman et al., 2000) .
The TIDA neurons arise from the dorsomedial arcuate nucleus and their axons terminate in the capillary bed of the external zone of the median eminence (ME), where DA diffuses and is transported to the anterior pituitary via long portal vessels. THDA neurons arise from the rostral arcuate nucleus, and their axons terminate on short portal vessels in the neural lobe and intermediate lobe of pituitary. PHDA neurons arise from the periventricular nucleus, and their axons terminate exclusively on short portal vessels in the intermediate lobe (Poletini et al., 2010) .
Dopamine binds to DA-D2 receptors on lactotrophs that are functionally linked to membrane channels and G proteins and suppresses the high secretory activity of these cells. A definite increase in PRL secretion occurs following lactotrophs escape from the inhibitory hypothalamic dopaminer-gic tone. Once PRL has been secreted, it feeds back on the hypothalamus to stimulate the synthesis and turnover of DA, as well as to promote the release of DA into pituitary portal blood (Poletini et al., 2010) . The action of DA on the PRL secretion is timedependent. Indeed, within seconds, DA increases potassium conductance and inactivates voltagesensitive calcium channels, resulting in membrane hyperpolarization and lowering the intracellular free calcium; within minutes to hours, DA decreases adenylcyclase activity, inosytol phosphate metabolism, arachidonic acid release and PRL gene expression. Within days, DA suppresses PRL cell proliferation (Stojilkovic et al., 2010) . Withdrawal of DA after short application evokes a rapid rebound increase of basal PRL secretion (Ben-Jonathan and Hnasko, 2001) . DA actions in lactotrophs depend on the gonadal steroid milieu in female rats. Oestrogen decreases the expression of DA-D2 receptors and number of Gi/o immunoreactive lactotrophs (Livingstone et al., 1998; Stojilkovic et al., 2010) . Also the stimulatory and inhibitory actions of DA on PRL release vary throughout the oestrous cycle and in the ovariectomized rats with the steroid replacement therapy (Stojilkovic et al., 2010) . On the other hand, in vivo experiments often yield conflicting results because prolonged exposure and high doses of oestradiol increases PRL release, PRL gene expression and number of lactotrophs by activating PRL short loop feedback mechanism. Also a rapid rebound of PRL secretion after withdrawal of DA is steroid-dependent (Ben-Jonathan and Hnasko, 2001; Sam and Frohman, 2008) .
Endothelin peptides, which are differentially expressed in tissues of the peripheral and central nervous system, have profound effects on prolactin secretion (Samson et al., 1990; Kanyicska et al., 1991; Samson and Skala, 1992; Kanyicska et al., 1995; Stojilkovic et al., 2010) . The endothelin receptors ETa are located on the lactotrophs (Stojilkovic et al., 2010) . Stimulation of these receptors transiently activates PRL release followed sustaining inhibition; in lactotrophs the inhibitory phase lasts for several hours. Interestingly, DA could also change the number of ETa receptors signals from inhibitory to stimulatory. ETa receptors might recouple to the inhibitory pathways coupled to DA-D2 receptors and thus ETs might replace DA as the primary inhibitory factor (Stojilkovic et al., 2010) .
Arginin-vasopresin peptide, which is synthesized in the dorsomedial portion of suprachiasmatic nucleus (SCN) (Moore et al., 2002; Morin et al., 2006) displays an inhibitory role on PRL secretion induced by oestradiol in female rats (Palm et al., 2001) .
Other neuropeptides, such bombesin like peptides, neurotensin, NPY inhibit PRL release by stimulating the TIDA neurons (Ben-Jonathan and Hnasko, 2001) . Their actions are often confounded by their ability to exert opposite effect on the pituitary lactotrophs. More specifically, bombesin-like peptides (neuromedins B and C, and ranatensin) may also play a role in the circadian rhythm of PRL release, acting via the SCN (Mai and Pan, 1995) . The central immunoneutralization of these peptides is provided by the rise in serum PRL (Ben-Jonathan and Hnasko, 2001) .
Neurotensin, like many neuropeptides, exerts a dual action on PRL: the central inhibition and peripheral stimulation (Pan et al., 1992) . Neurotensin centrally stimulates TIDA neurons and decreases in serum PRL (McCann and Vijayan, 1992) . The influence of NPY, the most abundant neuropeptide in the brain, on PRL release is similar to those of neurotensin, except that it does not mediate the PRL feedback effect on TIDA neurons (Freeman et al., 2000) . In MMQ cells of rats oestradiol increases the expression of DA-D2 receptors and might decrease PRL release (Stojilkovic et al., 2010) .
Current studies have revealed that anorectic and orexigenic hormones participate also in the control of prolactin secretion, although potential mechanisms account these processes are still not resolved.
The results indicate that effect of leptin on PRL release may be species-specific. It has been noted that leptin mediated the stimulation of PRL release in bovine adenohypophyseal explants in culture (Accorsi et al., 2007) but it had little effect on PRL secretion from primary culture of porcine anterior pituitary cells (Nonaka et al., 2007) . Circulating PRL increase in response to leptin treatment in rats and it is suggested that this effect is mediated by hypothalamic neurons as well as in direct inhibition of PRL release from pituitary gland (Yu et al., 1997; Gonzalez et al., 1999; Watanobe et al., 1999) . In sheep, seasonally breeding species, leptin can modulate PRL release from pituitary gland in vitro and its effect on PRL release is seasonally dependent . Centrally infused leptin decreased mean concentration of PRL slightly during short day and increased this hormone secretion during long photoperiod. Based on the foregoing results on sheep it is suggested that the central administration of leptin in ewes during long photoperiod might affect PRL secretion either by acting directly on pituitary lactotrophs or through the central modulation of neurochemical compounds released from hypothalamus. On the other hand, it has been documented that leptin is a very potent prolactin secretagogu in teleost pituitary culture (Tipsmark et al., 2008) .
Similarly, dual action of orexin, inhibitory or stimulatory, on PRL release has been observed in rats (Russell et al., 2000 (Russell et al., , 2001 . It has been documented that orexin A reduces PRL secretion but its action does not involve the hypothalamic dopaminergic neurons in rats (Russell et al., 2000) . However, in other experiments it has been shown a stimulatory influence of orexin on PRL release in these animals (Martyńska et al., 2006) . Indeed, the orexin antibodies completely suppress the PRL release and preovulatory PRL surge is also dependent upon physiological state (Kohsaka et al., 2001) . Injection of orexin in starved rats restored the concentration of PRL to normal levels (Kohsaka et al., 2001) .
In sheep, the PRL secretion from pituitary glands in culture under orexin treatment is seasonally dependent. Orexin has a stimulatory influence on PRL release from pituitary glands collected from lactating ewes during long days but it displays opposite effect on this hormone secretion in short day photoperiod .
Secretion of PRL is also highly dependent upon melatonin secretion from the pineal gland, which activity is fluctuated upon annual cycle of changing day length. This phenomenon is especially evident in seasonally breeding species. In sheep, the short day photoperiod, elevates plasma melatonin concentration which in turn leads to the inhibition in the secretion of PRL (Misztal et al., 1997; Morgan, 2000; Molik et al., 2007; Gomez-Brunet et al., 2008; Morgan and Hazlerigg, 2008; . Numerous data indicated that prolonged treatment with melatonin (i.e. subcutaneous implants) during the long photoperiod also suppressed PRL secretion either in ewes or rams (Lincoln and Maeda, 1992; Lincoln, 1994; Viguie et al., 1997; Molik et al., 2010) . This supports the view that the suppression of prolactin secretion followed by a partial recovery (partial refractoriness) is a normal response to a short-day melatonin signal and that this is due to the action of melatonin in the pituitary gland. Indeed, it has been shown that melatonin inhibits PRL, acting within the pars tuberalis (PT) of the pituitary gland and that a protein factor called tuberalin, which governs both the synthesis and release of prolactin, participates in this mechanism (Morgan, 2000) . A long-duration melatonin signal from short days, or a continuous melatonin signal from a melatonin implant, may suppress prolactin secretion by inhibiting the release of tuberalin from the PT. The refractory response could be due to the reduced responsiveness of the melatonin target cells in the pituitary and to the partial recovery of tuberalin secretion acting to restimulate the lactotrophs (Lincoln and Clarke, 1997) . Conversely, the short term melatonin infusion into the third ventricle of the brain has been shown to stimulate PRL release in anoestrous ewes (Misztal et al., 1997) .
Factors stimulating prolactin release
Thyrotropin-releasing hormone (TRH) is one of the earliest proposed candidates of hypothalamic origin that stimulates secretion of prolactin from the anterior pituitary gland (Neil and Nagy, 1994; Freeman et al., 2000) . TRH has been shown to potentiate PRL release from lactotrophs in a dose-dependent manner both in vitro and in vivo experiments (Bowers et al., 1971; Tashjian et al., 1971; Blake, 1974) . It can successfully promote pituitary PRL secretion in oestrogen-primed male rats (Piercy and Shin, 1980) , but not in normal male or lactating female (Grosvenor and Mena, 1980; Piercy and Shin, 1980; Riskind et al., 1984) . The concentration of TRH in portal blood is slightly elevated during the afternoon of proestrus (Fink et al., 1982) and passive immunoneutralization of endogenous TRH (administration of TRH antiserum) has been reported to partially inhibit (Koch et al., 1977) or delay the onset (Horn et al., 1985) of the proestrus PRL surge and attenuate the suckling-induced prolactin response (De Greef et al., 1987) . However, TRH antiserum only slightly decreases prolactin-releasing activity of the hypothalamic extract (Boyd, 1976) .
The major site of TRH action is at the pituitary level and is related to its well-established role as a prolactin releasing hormone, although TRH may also affect PRL secretion by acting within the central nervous system (Freeman et al., 2000) . It has been documented that central administration of TRH inhibits PRL secretion (Ohta et al., 1985) , most probably through the stimulation of TIDA neurons (Ikegami et al., 1992) . The existence of TRH-immunopositive neural projections from the paraventricular nucleus to the arcuate nucleus (Brownstein et al., 1982) suggests a possibility of a direct TRH/ dopamine interaction at the level of the hypothalamus. Furthermore, the literature data showing that transient dopamine antagonism (Haisenleder et al., 1991) or this hormone withdrawal (Martinez De La Escalera and Weiner, 1990) increases the stimulatory effect of TRH on PRL secretion. It should be noted that in physiological conditions the lactotrophs are exposed to reducing concentrations of dopamine, but not for the complete this hormone absence, thus the interpretation of presented data must be approached with a caution.
Recently much attention is paid to a group of peptides that have been identified in mammals (Hinuma et al., 1998; Iijima et al., 1999; Fuji et al., 1999; Maruyama et al., 1999; Ibata et al., 2000) , birds (Tachibana et al., 2011) , fishes (Fujimoto et al., 1998; Satake et al., 1999; Moriyama et al., 2002; Seale et al., 2002; Sakamoto et al., 2005) , amphibians (Sakamoto et al., 2006) as the prolactin releasing peptides (PrRPs). These animals have several forms of PrRPs with different numbers of amino acids (20, 25, 31, 32, 37) and different effects on prolactin release (Tachibana et al., 2011) .
In rats the PrRPs-31 stimulates exocytosis of prolactin selectively from type II and type III lactotrophs but not from type I PRL-producing cells (Christian et al., 2007) . These results indicate that respective receptors and signalling cascades required inducing PRL release. However, there are no still published results regarding the PrRPs-31 receptor expression in lactotroph subtypes (Christian et al., 2007) . On the other hand, it is well documented, that not all pituitary lactotrophs in rats express TRH receptors, suggesting the functional heterogeneity of these cells (Christian et al., 2007) . TRH receptors have been identified on type II and type III of lactotrophs but not any labelling was evident on type I. Other studies have revealed that the stimulatory influence of PrRPs-31 on PRL release in rats is rather low compared to TRH or VIP (Samson et al., 1998; Curlewis et al., 2002; Swinnen et al., 2005; Christian et al., 2007) .
The stimulatory effect of PrRPs-31 on PRL secretion was documented in vitro studies on dispersed pituitary cells taken from lactating rats (Hinuma et al., 1998) and in vivo in male and female rats . Other investigators, in turn, have no been able to confirm this effect on PRL release in the experiments both: in vivo -in male or female rats (Jarry et al., 2000; Seal et al., 2000) and in vitro -on cells collected from lactating and virgin females (Samson et al., 2000) ; only high concentration of PrRPs-31 was capable to increase PRL release from dispersed lactotrophs derived from virgin female rats (Samson et al., 1998) .
It should be noted that the PrRPs-31 action on PRL release may be species-specific. The PrRPs-31 has no stimulatory effect on PRL release in sheep (Curlewis et al., 2002) , but it is essential for secretion of this hormone in teleost fish (Sakamoto et al., 2003) . Chicken PrRPs-31/32 increases plasma PRL concentration in chicks when administered peripherally whereas infused centrally decreases PRL release, suggesting that in these animals PrRPs-31/32 has distinct effect on PRL secretion between tissue (Tachibana et al., 2011) . It is likely, that the PrRPs-31/32 in the chicken brain might function as a feedback regulator of PRL release. These differences, at least in part, might be caused by differences in the distribution of PrRPs and their receptors. It is very possible, given a fact a distinct tissue distribution for both the PrRP peptide and receptor messenger RNAs in rats (Fuji et al., 1999; Roland et al., 1999) . In RT-PCR analysis, rat PrRP receptor mRNA was detected in the central nervous system, and the highest expression was detected in the pituitary gland. In addition, in situ hybridization revealed that rat PrRP receptor mRNA was highly expressed in the anterior lobe of the pituitary. On the other hand, rat PrRP mRNA was most abundantly expressed in the medulla oblongata, while significant levels of expression were widely detected in other tissues (Fuji et al., 1999) .
Similarly, angiotensin II, oxytocin, ATP and acetylocholine are implicated in stimulatory influence on PRL release (Ben-Jonathan and Hnasko, 2001) . The stimulatory action of serotonin (5-HT) on PRL release involves 5HT 2A , 5HT 2C and 5HT 3C receptor subtypes (Balsa et al., 1998) . The current opinion is that 5-HT affects PRL secretion primarily by stimulating the release of prolactin releasing factors (Ben-Jonathan and Hnasko, 2001) . Opioid peptide stimulates also PRL release by inhibiting the TIDA neurons or promotes salsolinol action (Ben-Jonathan and Hnasko, 2001; Misztal et al., 2010b ). GABA appears to play a role in the control of basal and diurnal changes of TIDA neurons activity and contributes to increase PRL secretion (Lee and Pan, 2001) .
Suckling is a one among many other powerful stimulators for PRL secretion in mammals (Grattan, 2002; Misztal et al., 2008 Misztal et al., , 2010a . The stimulatory action of suckling on PRL release might result from many processes, which most important are two: a decrease of inhibitory effect of DA and other inhibitors of PRL release, and an increase of stimulatory secretagogue on lactotrophs and/or both of these events (Ben-Jonathan and Hnasko, 2001; Stojilkovic et al., 2010; Tachibana et al., 2011) .
Studies on rats have shown that the dopaminergic system in the hypothalamus during late pregnancy has reduced ability to respond to PRL (Grattan and Averill, 1995; Andrews et al., 2001) and that this impaired negative feedback is continued into lactation (Arbogast and Voogt, 1998; Anderson et al., 2006) , allowing the maintenance of increased PRL secretion to promote lactogenesis.
Subsequent works have indicated that the opioid peptides might be involved in this process. Indeed, the opioid peptides reduce hypothalamic dopaminergic system activity in rats by marked suppression of tyrosine hydroxylase gene expression during lactation (Arbogast and Voogt, 1998) . More recently, attention has been paid for a DA-derived product, salsolinol, (1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, Figure 1) , which stimulatory properties for prolactin secretion were described either in rodents or ruminants (Toth et al., 2001 (Toth et al., , 2002 Hashizume et al., 2008 a,b; Misztal et al., 2008 , 2010a Hasiec et al., 2012) .
In lactating ewes, the extracellular concentration of salsolinol in the infundibular nucleus/median eminence (IN/ME) increased in response to suckling stimulus and was closely related to suckling-induced increase in PRL secretion . No concentration of DA was detected in the perfusates collected from the IN/ME during this early period of lactation (4/5 week). Since the endogenous opioid peptides (EOP) antagonists, naloxone or naloxonazine, infused into the third ventricle of the brain of nursing sheep, diminished the concentration of salsolinol in the IN/ME and increased the release of DA (Misztal et al., 2010b) , it suggested that changes in the DA/salsolinol ratio in the hypothalamic dopaminergic system resulted from the transformation of DA to salsolinol and the EOP are a base of this process. Moreover, the infusion of salsolinol into the third brain ventricle stimulated both the PRL release in lactating ewes and expression of PRL mRNA in lactating ewes after 48 h of lamb weaning (Hasiec et al., 2012) . In turn, the infusion of 1-MeDIQ, a structural analogue of salsolinol, inhibited basal PRL release in nursing ewes and reduced suckling-induced prolactin surge (Misztal et al., 2010a) . 1-MeDIQ was proved to be very potent inhibitor of salsolinolinduced PRL release and blocked PRL release in suckling and stressed lactating rats (Bodnar et al., 2004) . Since the stimulatory action of salsolinol on PRL release might occur at the hypothalamic as well as at the pituitary level (Toth et al., 2001 (Toth et al., , 2002 Hashizume et al., 2008a; Misztal et al., 2008 Misztal et al., , 2010b Górski et al., 2010; Hasiec et al., 2012) it is assumed that salsolinol can act indirectly through modulation of the dopaminergic system in the hypothalamus as well as directly through stimulation of specific receptors in pituitary gland. Although exact salsolinol receptors have not been found on prolactin cells the stimulatory effect of salsolinol on PRL release from lactotrophs has been observed in the studies using cell culture systems in rats (Toth et al., 2001 ) and young 7-8-month old heifers (Hashizume et al., 2008a) but not on 1 month old animals (Hashizume et al., 2009) . Salsolinol stimulated prolactin secretion in hypophysectomized rats bearing anterior lobe transplants under the kidney capsule (Toth et al., 2001) . Recent in vivo and in vitro studies on the influence of salsolinol on PRL secretion revealed, that it increases PRL mRNA expression in the anterior pituitary gland, thus suggesting that salsolinol is involved in the stimulation of PRL biosynthesis (Hasiec et al., 2012) .
Studies curried out for comparison the characteristics of the PRL-releasing response to salsolinol and TRH revealed that in ruminants the mechanism(s) of the salsolinol induced release of PRL is different from the mechanism(s) of action of TRH (Hashizume et al., 2009 ). However, the relation between salsolinol and TRH has not fully elucidated and requires further research.
In summary, original research results presented briefly in this review demonstrate that the PRL producing cells are non-homologous group and they might secrete PRL, or GH and both of them. Most PRL cells are also heterogenous with respect to basal hormone release, electrical activity and responsiveness to secretagogues, depending upon physiological stage, place their action and gender. PRL is involved in regulation of many physiological functions displaying multimodal action as a growth factor, neurotransmitter, immunoregulator or hormone and is upon the regulation of many central and peripheral factors to keep its secretion on the sustainable level. 
